TX-MARY-KAY
22.12.2022 17:06:37 CET | Business Wire | Press release
Mary Kay recently announced its sustainability strategy – Enriching Lives Today for a Sustainable Tomorrow – which encompasses five pillars, 15 commitments, and over a decade of action. This strategy was developed with Mary Kay’s key stakeholders and is aligned with the United Nations’ Sustainable Development Goals, making Mary Kay an essential part of a global coalition to ensure a better future.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221222005031/en/
Mary Kay Inc. partners with local and global organizations to further their mission to enrich women’s lives and bring education opportunities to young women around the world.
As part of this overarching strategy and to continue its decades-long advocacy for women’s empowerment, education and entrepreneurship, Mary Kay is committed to providing 250,000 young women education opportunities by 2030. To further its mission of enriching women’s lives, partnerships and scholarships with local and global organizations in 2022 ensured young women around the world are provided with exceptional education opportunities to pursue their dreams.
2022 Mary Kay Inc. Partnerships/Programs included:
- Young Women in STEAM Grants – Six recipients received grants created to elevate young women in STEAM fields and encourage them to continue their passions and career pursuits. The 2022 recipients were from N. Macedonia, Germany, the Philippines, China, and Australia pursuing careers in everything from app development and architecture to physics and geothermal inventions.
- Young Women in STEAM Continuing Education Grant – As an extension of Mary Kay’s Young Women in STEAM grants and social campaign, Ivanna Hernandez, a 2021 grant recipient, was awarded a second grant to help further pursue her dream of becoming the first Latin American woman astronaut to go to Mars. She was featured in a documentary created to inspire young women to shoot for the stars – or Mars in this case!
- Society of Cosmetic Chemists Madam C. J. Walker Scholarship – Established to honor Walker, the first female, self-made millionaire who made her fortune by developing a line of cosmetics and hair care products for Black women. At the SCC 75th Annual meeting, Ms. A’Lelia Bundles, the great-great-granddaughter of Madam C.J. Walker, and Michelle Hines, Ph.D., Director of Product Formulation at Mary Kay, presented the Madam C. J. Walker Scholarships for under-represented minority students pursuing higher education in STEM disciplines related to the cosmetics and personal care industry. The award is supported by the Society of Cosmetic Chemists and partnered and funded by Mary Kay. The winning recipients included: Joy Rutherford, fifth-year PhD student and NIH Research Fellow; and Imani Elaine Porter, Hampton University, second-year undergraduate in biochemistry.
- Network for Teaching Entrepreneurship – Partnering to provide 47,000 youth globally with entrepreneurship curriculum and innovative thinking opportunities. Through support of 1) the Aspiring Entrepreneurs Program (U.S.) core program; 2) World Series of Innovation; and 3) World Series of Innovation Challenge Innovation Days, Mary Kay is helping to empower youth to reach their entrepreneurial dreams. In the 2021-2022 school year, Mary Kay sponsored the NFTE World Series of Innovation (WSI) where 21 teams of emerging social entrepreneurs won a total of $16,800 for their proposed solutions to seven challenges, each of which focused on advancing a Sustainable Development Goal. Sponsors of the seven innovation challenges included: Bank of the West, Citi Foundation, Mary Kay, Saint-Gobain North America, Ernst & Young, LLP (EY), Maxar Technologies, and PIMCO. The 2022 World Series of Innovation Challenge launched in September 2022 and Mary Kay is participating for a third year tackling SDG 14: Life Below Water.
- City of Lewisville, IncubatorEDU – In partnership with the Lewisville Independent School District (LISD), IncubatorEDU offers a robust entrepreneurship curriculum to Lewisville High School students. Community mentors and an end-of-year pitch event provide the students with real-life entrepreneurial experience and education opportunities.
- Academy of Marketing Science – For more than 25 years, Mary Kay has supported the Mary Kay Dissertation and Dissertation Proposal Awards at the annual Academy of Marketing Science (AMS) conference where doctoral student participants showcase their successfully defended dissertations and receive a monetary award and critical peer feedback to improve their chances of publishing their work in academic journals in the future.
- Ursuline Academy of Dallas – Mary Kay Ash Endowed Scholarship – Scholarship awarded annually to support girls with an education that equips them with the skills and confidence needed to do great things.
- Army Scholarship Foundation - Mary Kay Corporation Honorary Scholarship – Scholarship awarded annually to deserving sons and daughters of US Army soldiers and Army veterans, and to spouses of enlisted active-duty soldiers.
- Hispanic Scholarship Fund – Scholarship awarded annually to support and empower students and parents with the knowledge and resources to successfully complete a higher education, while providing support services and scholarships to as many exceptional students, HSF scholars and Alumni as possible.
About Mary Kay
One of the original glass ceiling breakers, Mary Kay Ash founded her dream beauty company in 1963 with one goal: enriching women’s lives. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. As an entrepreneurship development company, Mary Kay is committed to empowering women on their journey through education, mentorship, advocacy, networking, and innovation. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skincare, color cosmetics, nutritional supplements, and fragrances. Mary Kay believes in enriching lives today for a sustainable tomorrow, partnering with organizations from around the world focusing on promoting business excellence, supporting cancer research, advancing gender equality, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Learn more at marykayglobal.com, find us on Facebook, Instagram, and LinkedIn, or follow us on Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221222005031/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom